Health Trials

Clinical trials

5

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.

Participants needed: 344
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Insmed IncorporatedUpdated: Jun 10, 2026Locations: 2
Eligibility criteria

Idiopathic PAH [+16]

Diagnosis of PH WHO Groups 2, 3, 4, or 5, or subtypes of PH WHO Group 1 other th... [+6]

Read more
Status: Available

An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

The purpose of this study is to provide continued access to TPIP for participants who have successfully completed the open-label extension (OLE) studies of INS1009-203 for PAH or INS1009-212 for PH-ILD.

Trial details
Age: 18+Biological sex: AllType: Expanded AccessSponsor: Insmed IncorporatedUpdated: Jun 10, 2026
Eligibility criteria

The participant is ineligible for or cannot be treated satisfactorily with alter... [+6]

Read more
Status: Not yet recruiting

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

The primary purpose of the study is to determine the effect of mild, moderate, and severe hepatic impairment on the PK of total treprostinil palmitil (TP) and treprostinil (TRE) following a single dose of 80 micrograms (μg) TPIP, when compared to normal hepatic function.

Participants needed: 30
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Insmed IncorporatedUpdated: Jun 11, 2026
Eligibility criteria

Body mass index between 18.0 and 40.0 kilograms per square meter (kg/m²), inclus... [+4]

History of stomach or intestinal surgery or resection that would potentially alt... [+9]

Read more
Status: Recruiting

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.

Participants needed: 344
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Insmed IncorporatedUpdated: May 27, 2026Locations: 109
Eligibility criteria

Diagnosis of PH World Health Organisation (WHO) Group 3 associated with ILD [inc... [+7]

Diagnosis of Pulmonary Hypertension WHO Groups 1, 2, 4, or 5, or subtypes of PH... [+11]

Read more
Status: Not yet recruiting

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).

Participants needed: 344
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Insmed IncorporatedUpdated: May 26, 2026
Eligibility criteria

Participants who have completed the lead-in PH-ILD TPIP Study INS1009-311 (NCT07... [+2]

Participants who experienced any adverse events (AEs) evaluated as causally rela... [+4]

Read more